Ever wanted to understand game theory?

Ever wanted to understand game theory?

Perfect timing with the availability of infocomix. Within „game theory“ the authors were able to transfer the basic concepts of game theory in an easy and non-mathematical way! Fun to read also for experienced game theorists!!

We at MArS apply game theory in our MArS negotiation boot camp to prepare clients optimally for the negotiations with payers! Contact us!!!

The book is available also on Amazon.

MArS supporting the reform of the Egyptian health care system

Great honor to have been invited to a Pharmacoeconomics workshop in November to Cairo, Egypt. Dr. Walzer presented the situation on evidence-based medicine, HTA and reference pricing in Europe as well as the introduction into value-based pricing in the context of health economics.

The course was well organized by Accsight and their team with a very open-minded Egyptian payer audience.

Big discussions paving the way for a new Egyptian health care system by 2030!!!

Risk share agreements and application in global reimbursement decisions

Which risk share agreements are available and are those applied in global reimbursement decisions?

Risk Share Agreements (RSAs) are defined as agreements between a payer and a manufacturer where the price level is related to the actual future performance of the product. In the last years RSAs were introduced and applied in various jurisdictions. RSAs in Australia, Canada, Italy, Spain, UK and the US were systematically searched for. They were clustered into the type of RSA per country and compared to each other.

Download the poster including all results: Walzer_et_al._Risk_Share_Agreements_ISPOR_2015

A systematic comparison of AMNOG decisions

On January 1st 2011 Act on the Reform of the Market for Medicinal Products (AMNOG) came into force in Germany. The aim of AMNOG is to curb the rapidly rising expenditure for pharmaceutical products by the statutory health insurance funds.

Since the introduction of AMNOG, more than 100 IQWiG recommendations and G-BA decisions on the early benefit assessment have been published. In various assessments, the IQWiG recommendation and the related G-BA decision differed in terms of decision argumentation and actual result.

In this study, these differences were systematically analyzed in order to draw conclusions for future proceedings and optimization of the process.

Download the poster: Vollmer_et_al._IQWiG_vs_G-BA_ISPOR_2015

30 Posters with Medvance

ISPOR ahead – we are just finalizing our eight MArS posters!!

With our Medvance mates we have even close to 30 posters this year!!! And all Medvance posters presented at ISPOR you can find at one place!!! Market access and pricing strategy for Europe developed and executed by local, independent consultancies – only with Medvance!!! Contact us.

Get all posters at our Medvance site: https://medvance.eu/conferences/